CellCarta China Updates on PD-L1 Immunohistochemistry

This document is a newsletter providing updates from CellCarta regarding their laboratory operations in Jining, China, particularly focusing on Programmed Death-Ligand 1 (PD-L1) immunohistochemistry. It details the historical context of the BluePrint Phase 2 (BP2) study, which compared five PD-L1 immunohistochemistry assays and confirmed the reliability of digital image scoring. The newsletter outlines the growth of PD-1/L1 monoclonal antibody clinical trials from 2017 to 2021, highlighting the increase in trials and the current status of PD-L1 related trials in China. It also discusses advancements in digital pathology since the BP2 study and mentions the impact of the COVID-19 pandemic on remote digital pathology practices. The document notes the participation of CellCarta in over 40 companion diagnostic studies and the ongoing developments in their laboratory capabilities. Furthermore, it provides information about upcoming conferences and the growth of their team in Jining.